Epidemiology of immune-mediated inflammatory diseases: Incidence, prevalence, natural history, and comorbidities

Journal of Rheumatology

Volumn 37, Issue SUPPL. 85, 2010, Pages 2-10

  El Gabalawy, Hani ^a   Guenther, Lyn C ^b   Bernstein, Charles N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Epidemiology; Immune mediated inflammatory diseases; Incidence; Prevalence

Indexed keywords

ETANERCEPT; HLA B27 ANTIGEN; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ALCOHOLISM; ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; COMORBIDITY; DEVELOPING COUNTRY; ENTERITIS; ENVIRONMENTAL FACTOR; ETHNICITY; GENDER; HEART INFARCTION; HISTORY; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; INCIDENCE; INFLAMMATORY DISEASE; IRITIS; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SOCIAL STATUS; ULCERATIVE COLITIS; CARDIOVASCULAR DISEASE; DISEASE COURSE; FEMALE; HEALTH; IMMUNOLOGY; INFLAMMATION; MALE; SEX RATIO;

CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATION; MALE; PREVALENCE; SEX DISTRIBUTION; WORLD HEALTH;

EID: 77957887758     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091461     Document Type: Review

References (79)

1. Kuek A, Hazleman BL, Ostör AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251-60.
2. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-43.
3. Schuma AA. Autoimmune rheumatic diseases in women. J Am Pharm Assoc 2002;42:612-24.
4. Lambert NC, Stevens AM, Tylee TS, Erickson TD, Furst DE, Nelson JL. From the simple detection of microchimerism in patients with autoimmune diseases to its implication in pathogenesis. Ann NY Acad Sci 2001;945:164-71.
5. Castagnetta L, Granata OM, Traina H, Cocciadiferro L, Saetta A, Stefano R, et al. A role for sex steroids in autoimmune diseases: a working hypothesis and supporting data. Ann NY Acad Sci 2002;966:193-203.
6. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81.
7. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6.
8. Ferucci ED, Templin DW, Lanier AP. Rheumatoid arthritis in American Indians and Alaska Natives: a review of the literature. Semin Arthritis Rheum 2005;34:662-7.
9. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36:182-8.
10. Shichikawa K, Inoue K, Hirota S, Maeda A, Ota H, Kimura M, et al. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum Dis 1999;58:751-6.
11. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625-31.
12. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009;11:229.
13. Gabriel SE, Crowson CS, Maradit Kremers H, Therneau TM. The rising incidence of rheumatoid arthritis [abstract]. Arthritis Rheum 2008;58 Suppl:S453.
14. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002;41:793-800.
15. Carmona L, Villaverde V, Hernández-García C, Ballina J, Gabriel R, Laffon A; EPISER Study Group. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology 2002;41:88-95. (Pubitemid 34537926)
16. Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999;42:415-20.
17. Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson LA, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease: a meta analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 2004;50:400-12.
18. Lawrence RC, Everett DF, Benevolenskaya LI, Boyer GS, Erdesz S, Templin DW, et al. Spondyloarthropathies in circumpolar populations: I. Design and methods of United States and Russian studies. Arctic Med Res 1996;55:187-94.
19. Benevolenskaya LI, Boyer GS, Erdesz S, Templin DW, Alexeeva LI, Lawrence RC, et al. Spondylarthropathic diseases in indigenous circumpolar populations of Russia and Alaska. Rev Rhum Engl Ed 1996;63:815-22.
20. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64 Suppl 2:ii18-23.
21. Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002;46:867-73.
22. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6.
23. Enerback C, Martinsson T, Inerot A, Wahlström J, Enlund F, Yhr M, et al. Evidence that HLA-Cw6 determines early onset of psoriasis, obtained using sequence-specific primers (PCR-SSP). Acta Derm Venereol 1997;77:273-6.
24. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl II:ii14-ii17.
25. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Maradit Kremers H. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population based study. J Rheumatol 2009;36:361-7.
26. Bernstein CN, Blanchard JF. Epidemiology of inflammatory bowel disease. In: Cohen RD, editor. Clinical gastroenterology: Inflammatory bowel disease: diagnosis and therapeutics. Totowa, NJ: Humana Press Inc.; 2003:17-32.
27. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-68.
28. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
29. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology 1991;100:143-9.
30. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 2008;57:1185-91.
31. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006;12:6102-8.
32. Blanchard JF, Bernstein CN, Wajda A, Rawsthorne P. Small area variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis. Am J Epidemiol 2001;154:328-35.
33. Wigley RD, Maclaurin BP. A study of ulcerative colitis in New Zealand, showing a low incidence in Maoris. Br Med J 1962;2:228-31.
34. Robinson D Jr, Hackett M, Wong J, Kimball AB, Cohen R, Bala M; IMID Study Group. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 2006;22:989-1000.
35. Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis 2008;14:738-43.
36. Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic and environmental factors. J Rheumatol 2001;28:2667-73.
37. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:885-906
38. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
39. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40.
40. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402-11.
41. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
42. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005;52:412-20.
43. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
44. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
45. Karlson EW, Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum 1999;42:910-17.
46. Criswell LA, Merlino LA, Cerhan JR, Mikuls TR, Mudano AS, Burma M, et al. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Med 2002;112:465-71.
47. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010;69:70-81.
48. Doran M, Crowson C, Pond G, O'Fallon W, Gabriel S. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
49. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81.
50. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64.
51. Symmons DP. Mortality in rheumatoid arthritis. Br J Rheumatol 1988;27 Suppl 1:44-54.
52. Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol 1982;11:81-6.
53. Koota K, Isomake H, Mutru O. Death rate and causes of death in RA patients during a period of five years. Scand J Rheumatol 1977;6:241-4.
54. Isomaki HA, Mutru O, Koota K. Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 1975;4:205-8.
55. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007;66:308-12.
56. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-72.
57. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9.
58. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167:1670-5.
59. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-34.
60. Ji J, Shu X, Sundquist K, Sundquist J, Hemminki K. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer 2009;100:1499-502.
61. Kirby B, Richards HL, Mason DL, Fortune DG, Main CJ, Griffiths CE. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008;158:138-40.
62. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008;7:373-7.
63. van Leuven SI, Hezemans R, Levels JH, Snoek S, Stokkers PC, Hovingh GK, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res 2007;48:2640-6.
64. Papa A, Danese S, Urgesi R, Grillo A, Guglielmo S, Roberto I, et al. Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2006;10:7-11.
65. Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 2008;6:41-5.
66. Roifman I, Sun YC, Fedwick JP, Panaccione R, Buret AG, Liu H, et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009;7:175-82.
67. Romanato G, Scarpa M, Angriman I, Faggian D, Ruffolo C, Marin R, et al. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment Pharmacol Ther 2009;29:298-307.
68. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30.
69. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol 2007;102:662-7.
70. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8.
71. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72.
72. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
73. Loftus EV Jr. Mortality in inflammatory bowel disease: peril and promise. Gastroenterology 2003;125:1881-3.
74. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther 2007;25:861-70.
75. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-7.
76. Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30.
77. Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8.
78. Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12.
79. Bathon J, Fleischmann R, Peloso P, Chon Y, Hooper M, Lin S. Rates of cardiovascular events in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials [abstract]. Arthritis Rheum 2006;54 Suppl: S188.